Phosphonortonic 20% Injectable Solution

País: Irlanda

Idioma: anglès

Font: HPRA (Health Products Regulatory Authority)

ingredients actius:

Toldimfos sodium trihydrate

Disponible des:

Vetoquinol Ireland Limited

Codi ATC:

QA12CX90

Designació comuna internacional (DCI):

Toldimfos sodium trihydrate

Dosis:

20 percent weight/volume

formulario farmacéutico:

Solution for injection

tipo de receta:

LM: Licensed Merchant as defined in relevant national legislation

Grupo terapéutico:

Cattle, Horses

Área terapéutica:

toldimfos

indicaciones terapéuticas:

Vitamins and minerals

Estat d'Autorització:

Authorised

Data d'autorització:

1989-10-01

Fitxa tècnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Phosphonortonic 20% Injectable Solution.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses, cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Phosphonortonic supplies organic phosphorus and is indicated in the
treatment of disorders of phosphorus metabolism in
horses and cattle.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance.
Do not use the product in animals suffering from renal failure.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
None.
Each ml contains:
Active Substance
Toldimfos sodium trihydrate
20.00 % w/v
Excipients
Anhydrous Sodium Sulphite
0.20 % w/v
Phenethyl alcohol
1.00 % w/v
For a full list of excipients see 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_4_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_6_
_0_
_0_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
The product may be used in lactating animals.
No data are available on the effect of the product in pregnancy.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF